Acceleron Pharma Inc (XLRN) : Novo As scooped up 217,970 additional shares in Acceleron Pharma Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 903,833 shares of Acceleron Pharma Inc which is valued at $36,316,010.Acceleron Pharma Inc makes up approximately 3.26% of Novo As’s portfolio.
Other Hedge Funds, Including , Pacad Investment Ltd. reduced its stake in XLRN by selling 2,400 shares or 61.54% in the most recent quarter. The Hedge Fund company now holds 1,500 shares of XLRN which is valued at $60,270. Acceleron Pharma Inc makes up approx 0.01% of Pacad Investment Ltd.’s portfolio.Bessemer Group Inc reduced its stake in XLRN by selling 3 shares or 2.52% in the most recent quarter. The Hedge Fund company now holds 116 shares of XLRN which is valued at $4,220.California State Teachers Retirement System boosted its stake in XLRN in the latest quarter, The investment management firm added 600 additional shares and now holds a total of 58,069 shares of Acceleron Pharma Inc which is valued at $1,960,409.Blackrock Institutional Trust Company N.a. boosted its stake in XLRN in the latest quarter, The investment management firm added 26,834 additional shares and now holds a total of 757,640 shares of Acceleron Pharma Inc which is valued at $20,842,676.Verde Servicos Internacionais S.a. reduced its stake in XLRN by selling 14,433 shares or 11.73% in the most recent quarter. The Hedge Fund company now holds 108,632 shares of XLRN which is valued at $3,243,752. Acceleron Pharma Inc makes up approx 0.33% of Verde Servicos Internacionais S.a.’s portfolio.
Acceleron Pharma Inc closed down -0.19 points or -0.50% at $37.96 with 4,55,457 shares getting traded on Monday. Post opening the session at $37.74, the shares hit an intraday low of $36.44 and an intraday high of $38.16 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Acceleron Pharma Inc reported $-0.55 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.54.Analysts expectations of $ 4.19.
Many Wall Street Analysts have commented on Acceleron Pharma Inc. Citigroup Initiated Acceleron Pharma Inc on Sep 29, 2016 to “Neutral”, Price Target of the shares are set at $40.
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s research focuses on key natural regulators of cellular growth and repair particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how including its knowledge of the TGF-b superfamily and its internal protein engineering and manufacturing capabilities the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.